Clinical Trial Update: Tavilermide Ophthalmic Solution for the Treatment of Dry Eye [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for tavilermide ophthalmic solution in dry eye conditions; study completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye
• Keratoconjunctivitis Sicca

Drugs mentioned

• Tavilermide ophthalmic solution (tavilermide)

Snippet

Sponsor: Mimetogen Pharmaceuticals USA, Inc. | Conditions: Keratoconjunctivitis Sicca, Dry Eye | Phase 3 | Status: COMPLETED | Results posted: 2023-03-09